EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSEEEG00000000991
Gene Symbol: HTR5A
2 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSEEEG00000019869
Gene Symbol: HTR7
4 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSEEEG00000014831
Gene Symbol: LOC113579512
3 Cross references
152 Possible Orthologues:

60s Ribosomal Protein L4-B-Like

Ensembl ID : ENSEEEG00000003795
Gene Symbol: LOC113570826
4 Cross references
341 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSEEEG00000020461
Gene Symbol: ARAF
4 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSEEEG00000005415
Gene Symbol: ABL1
4 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSEEEG00000010193
Gene Symbol: ADAM17
4 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSEEEG00000016971
Gene Symbol: ADAM17A
4 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSEEEG00000018766
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSEEEG00000022766
Gene Symbol: ADRM1
4 Cross references
193 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSEEEG00000024376
Gene Symbol: ADRM1
4 Cross references
131 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSEEEG00000021477
Gene Symbol: AKT1
4 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).